Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.

1. Details of entrustment contract

As per this contract, FANCL will develop a multi-component cell culture model system derived from human iPS cells in collaboration with ReproCELL and employ the technology to focus on anti-aging drug development. FANCL researches, develops, manufactures, and sells cosmetics and nutritional supplements; in the future, FANCL will use the cell technology to advance its basic research and product development.

Human iPS cells hold great promise not only for regenerative medicine, but as a tool for product development applicable to a variety of fields. A key strategy of ReproCELL is to apply the accumulated corporate human iPS cell know-how to development innovative tools for use in a variety of medical and other business applications.

2. Schedule

Date of contract formation and business start date: November 16, 2016

3. Partner overview

(1) Name FANCL Corp.
(2) Location 89-1 Yamashita-chou, Naka-ku, Yokohama
(3) Name & position of representative Representative Director and President/CEO Kazuyoshi Miyajima
(4) Business activities Research, development, manufacture, and sales of cosmetics, supplements, and health foods
(5) Capital Stock 10,795,000,000 yen
(6) Date founded August 18, 1981
(7) Major stockholders and percentage of stock held KI Corp. (13.05%)
Kenji Ikemori (8.76%)